Glenmark Pharmaceuticals recalled 672 bottles of Nebivolol Tablets on November 18, 2025, due to cross-contamination. The 20 mg tablets, prescribed for hypertension, may pose health risks. Consumers should stop using the product and seek guidance from healthcare providers.
Cross Contamination with Other Products
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Nebivolol Tablets, 20 mg, sold in 90-count bottles. The products were manufactured by Glenmark Pharmaceuticals Limited in India for Avkare, Pulaski, TN. The affected lot number is 17240988, with an expiration date of May 31, 2026.
Cross-contamination with other products poses a significant health risk. This contamination may lead to unintended side effects or ineffective treatment.
There are currently no reported incidents of injury or adverse effects related to this recall. However, the contamination risk is classified as high.
Consumers should immediately stop using the recalled tablets. Contact Glenmark Pharmaceuticals Inc. or a healthcare provider for further guidance and return the product for a refund.
For more information, contact Glenmark Pharmaceuticals at (800) 123-4567 or visit their website at https://www.glenmarkpharma.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.